Jamieson Wellness Celebrates a Century of Improving the World's Health and Wellness

 

  Company kicks off the Jamieson brand's 100 th year with commitments for a sustainable future  

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) is celebrating the 100 th anniversary of its flagship brand, Jamieson Vitamins, with long-term plans for the creation of a sustainable future.

 

"We are incredibly proud of this historic milestone we have reached as a Company in 2022," said Mike Pilato, President and CEO of Jamieson Wellness. "What began in 1922 as a small, family-owned brand is now Canada's number one consumer health brand with products available in more than 45 countries around the world. I am grateful to the Jamieson team and our retail partners for their hard work and passion for building this brand together, and to our consumers for the century of trust they have placed in us for their health and wellness needs.

 

"While we are celebrating this achievement this year, we also recognize that we have a responsibility to forge a sustainable path for our next 100 years and the generations to come. As such, we are committing to a 50% emissions reduction by 2030, and to establishing a formal action plan to reach Net Zero by 2050. These goals are aligned to the United Nations Paris Agreement goals, and as we enter our 100 th year, projects have already begun to help us achieve them."

 

The Company has released an environmental, social and governance (ESG) document highlighting significant achievements in its diversity and inclusion efforts, as well as recent additions and improvements to its governance practices. It also identifies new sustainability projects currently underway and targeted for completion by 2030, including:

 
  • increasing recycled content in all branded packaging by 50%

  •  
  • reducing packaging cartons by 50%

  •  
  • reducing shipper corrugate content by 20%

  •  
  • reducing landfill waste by 75%
  •  

The complete document with additional details on these and the Company's other ESG projects can be found in the presentations section of the Company's corporate website or accessed directly here .

 

"We know that this is not going to be a simple or straightforward process, but as we look to expand our leadership beyond this 100-year mark we believe it is the right thing to do, and we welcome the challenge of creating real and positive change," said Mr. Pilato. "We are excited about the plans we have in place and look forward to sharing our progress as we begin another century of improving the world's health and wellness."

 

  About Jamieson Wellness Inc.  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2021 and under the "Risk Factors" section in the Company's MD&A dated November 3, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 

  

  

  Investor and Media Contact:  
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×